← All Biogen INC filings

Biogen INC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
BIIB
Biogen INC
SCHEDULE: Biogen Completes Apellis Pharmaceuticals Acquisition
Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger, marking an exit filing for Biogen.
NASDAQ
BIIB
Biogen INC
SCHEDULE: Biogen to Acquire Apellis Pharmaceuticals in $41 Billion Deal
Biogen Inc. announced its definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right (CVR) per share, valuing the company at approximately $41 billion.
NASDAQ
BIIB
Biogen INC
SCHEDULE: Biogen Divests Entire Stake in Sage Therapeutics
Biogen Inc. and Biogen MA Inc. have fully divested their 9.941% beneficial ownership in Sage Therapeutics, Inc. by selling all 6,241,473 shares at $8.53 per share.
NASDAQ
BIIB
Biogen INC
SCHEDULE: Biogen to Tender Sage Therapeutics Shares After Failed Acquisition Bid
Biogen Inc. plans to tender its 10% stake in Sage Therapeutics, Inc. following the rejection of its acquisition proposal and Sage's subsequent merger agreement with Supernus Pharmaceuticals, Inc.
NASDAQ
BIIB
Biogen INC
SCHEDULE 13D: Biogen Proposes Cash Acquisition of Sage Therapeutics at $7.22 Per Share, Building on Existing Collaboration
Biogen Inc. and its subsidiary Biogen MA Inc. have submitted a non-binding proposal to acquire all outstanding shares of Sage Therapeutics, Inc. not currently owned by them for $7.22 per share in cash.